B-cell lymphomas account for roughly 85% of all Non-Hodgkin Lymphoma diagnoses — and they are the cancers most directly tied to Roundup in the federal MDL. If you used Roundup and were diagnosed with Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Burkitt Lymphoma, or Waldenström Macroglobulinemia, you may have a powerful claim against Monsanto and Bayer.
B-cell lymphomas start in the B lymphocytes — the immune cells that make antibodies. Glyphosate causes oxidative stress and DNA damage in these same cells, which is the mechanistic core of the IARC's "probably carcinogenic" classification. Below are the B-cell subtypes most often seen in Roundup cases.
DLBCL is the most common form of NHL, accounting for roughly 30% of all NHL diagnoses in the United States. It is aggressive and fast-growing, but with intensive chemotherapy regimens like R-CHOP, complete responses and long remissions are common. DLBCL is the diagnosis we see most often in Roundup plaintiffs.
Follicular Lymphoma is the most common indolent (slow-growing) B-cell NHL and the second most common NHL subtype overall. Multiple agricultural cohort studies have found a particularly strong association between glyphosate exposure and Follicular Lymphoma.
A family of indolent B-cell lymphomas arising in the marginal zone of lymphoid tissue. Includes splenic Marginal Zone Lymphoma, nodal Marginal Zone Lymphoma, and extranodal MALT lymphoma (which can develop in the stomach, salivary glands, lung, thyroid, skin, and orbit).
An aggressive B-cell lymphoma that arises from cells in the mantle zone of the lymph node and is defined by a characteristic t(11;14) translocation and cyclin D1 overexpression. Often presents at advanced stage with bone marrow, GI, and lymph node involvement.
Rare but extremely aggressive B-cell lymphoma defined by a c-MYC translocation. Burkitt has one of the fastest doubling times of any human cancer and requires intensive multi-agent chemotherapy.
An indolent B-cell lymphoma in which malignant lymphoplasmacytic cells produce IgM. When IgM levels are elevated and clinical features are present, the diagnosis is Waldenström Macroglobulinemia.
SLL is the lymph-node presentation of Chronic Lymphocytic Leukemia (CLL) — the same disease, different presentation. We handle both as Roundup cases.
A rare, slow-growing B-cell leukemia named for the hair-like projections seen on the abnormal cells under a microscope. Strongly responsive to purine analog therapy.
Why pathology matters here
B-cell lymphomas are diagnosed by a combination of histology, immunohistochemistry (CD20, CD10, CD5, BCL-2, BCL-6, cyclin D1, MUM1, Ki-67), flow cytometry, and molecular studies (BCL2, MYC, BCL6 rearrangements). Herb Borroto, M.D., J.D., reads these reports personally as part of every Roundup B-cell lymphoma case — confirming the subtype and the strength of the causation argument.
B-cell lymphoma cases against Monsanto turn on two questions: was the product defective, and did it cause this person's cancer? Most firms run only the second half of that fight — and only the failure-to-warn version of the first half. We run the whole field.
Glyphosate-based Roundup is unreasonably dangerous as designed. No warning could make it safe for everyday spraying. That is the strict liability theory we have used to win 9-figure tobacco recoveries.
Herb Borroto, M.D., J.D., reads your DLBCL or Follicular Lymphoma pathology report as a physician — not through an outsourced expert. That is a direct line from your slide to the jury.
Alex Alvarez is Board Certified by the National Board of Trial Advocacy. Every B-cell lymphoma case is built to be tried — which is what drives Monsanto to resolve fairly.
DLBCL, Follicular, Marginal Zone, Mantle Cell, Burkitt, Lymphoplasmacytic / Waldenström, SLL, or Hairy Cell Leukemia.
Regular occupational or residential Roundup use. Farmers, applicators, landscapers, groundskeepers, golf-course staff, nursery workers, and homeowners who sprayed regularly all qualify.
Most states give 2 to 4 years from diagnosis (or, in some jurisdictions, from when the link to Roundup could reasonably have been discovered).
If a loved one used Roundup and died from a B-cell lymphoma, surviving family members may file a wrongful death claim.
Herb Borroto reads the slide as a physician — and builds the case as a lawyer. Free, confidential, no obligation.
Get Your Free Case ReviewAll major B-cell NHL subtypes can support a Roundup claim. The most common in the federal Roundup MDL are Diffuse Large B-cell Lymphoma (DLBCL) and Follicular Lymphoma. Other qualifying subtypes include Marginal Zone Lymphoma (splenic, nodal, MALT), Mantle Cell Lymphoma, Burkitt Lymphoma, Lymphoplasmacytic Lymphoma / Waldenström Macroglobulinemia, Small Lymphocytic Lymphoma, and Hairy Cell Leukemia. Herb Borroto, M.D., J.D., reads the immunohistochemistry, flow cytometry, and molecular reports personally to confirm the subtype.
Diffuse Large B-cell Lymphoma is diagnosed on a tissue biopsy showing large, atypical B-cells, with confirmation by immunohistochemistry (CD20+, CD79a+) and often FISH for MYC, BCL2, and BCL6 rearrangements. DLBCL is the most common NHL subtype and the diagnosis we see most often in Roundup plaintiffs. The pathology report is the foundation of the case. Herb Borroto, M.D., J.D., reads it personally before we file.
Yes. Follicular Lymphoma is the second most common NHL subtype overall and has a particularly strong association with glyphosate exposure in agricultural cohort studies. Patients in active treatment, in remission, in relapse, and surviving family of patients who died from Follicular Lymphoma all may have viable claims.
Most B-cell lymphoma cases against Monsanto are framed as failure-to-warn — meaning the lawsuit argues Monsanto should have warned consumers. The Alvarez Law Firm pursues failure-to-warn but leads with strict product liability: that Roundup, as designed, is unreasonably dangerous and caused the lymphoma regardless of what the label said. The same defective-product framework drove our $100M+ tobacco recoveries.
Transformation — most commonly Follicular Lymphoma transforming to DLBCL — is recognized in the Roundup MDL. Both the original indolent diagnosis and the subsequent transformation are part of the medical history we work with, and the case is built on the most aggressive disease the patient faces.
Other Roundup-linked cancers, our defective-product strategy, and the trial team behind every case.
The cancer most strongly tied to Roundup. Who qualifies, NHL subtypes, and filing deadlines.
CLL, SLL, and Hairy Cell Leukemia after glyphosate exposure.
Plasma cell cancers in farmers and applicators — the agricultural exposure link.
The defective-product framework that drove our $100M+ tobacco recoveries — applied to Monsanto.
Alex Alvarez, Board Certified Civil Trial Lawyer — and Herb Borroto, M.D., J.D.
DLBCL, Follicular Lymphoma, and the other B-cell NHL subtypes are at the center of the federal Roundup MDL. We attack the case under strict product liability — the same defective-product framework we have used to take more than $100 million from Big Tobacco.
Tell us what happened. We respond within 24 hours.
Your information is confidential. Submitting this form does not create an attorney-client relationship.
All factual claims on this page about B-cell lymphomas, glyphosate, and Roundup litigation are supported by the following authoritative primary sources.
External references for educational purposes only. Citation does not imply endorsement of this firm by the cited organizations.
